Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets.
about
Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded heartsDeregulation of RGS2 in cardiovascular diseasesProtective effect of silymarin against chemical-induced cardiotoxicityMitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.Anti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockadeThe ral exchange factor rgl2 promotes cardiomyocyte survival and inhibits cardiac fibrosisMEF2C silencing attenuates load-induced left ventricular hypertrophy by modulating mTOR/S6K pathway in miceExogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathwayMitochondrial fission is required for cardiomyocyte hypertrophy mediated by a Ca2+-calcineurin signaling pathway.Reduction of Na/K-ATPase affects cardiac remodeling and increases c-kit cell abundance in partial nephrectomized mice.Cardiac damage in athlete's heart: When the "supernormal" heart fails!Effects of adiponectin deficiency on structural and metabolic remodeling in mice subjected to pressure overload.Modulation of mitochondrial proteome and improved mitochondrial function by biventricular pacing of dyssynchronous failing hearts.Mitochondrial pruning by Nix and BNip3: an essential function for cardiac-expressed death factorsLow-intensity aerobic interval training attenuates pathological left ventricular remodeling and mitochondrial dysfunction in aortic-banded miniature swineRac-induced left ventricular dilation in thyroxin-treated ZmRacD transgenic mice: role of cardiomyocyte apoptosis and myocardial fibrosis.Pulmonary vascular pressure profiles in broilers selected for susceptibility to pulmonary hypertension syndrome: age and sex comparisons.Peroxisome proliferator-activated receptor (PPAR) gene profiling uncovers insulin-like growth factor-1 as a PPARalpha target gene in cardioprotection.Cardiomyocyte p65 nuclear factor-κB is necessary for compensatory adaptation to pressure overloadmicroRNA-22 promotes heart failure through coordinate suppression of PPAR/ERR-nuclear hormone receptor transcription.Mitochondrial fission and fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblastsMuscle KATP channels: recent insights to energy sensing and myoprotectionThe direct incorporation of perfusion defect information to define ischemia and infarction in a finite element model of the left ventricle.Classic studies of cultured cardiac myocyte hypertrophy: interview with a transformerThe antioxidant compound tert-butylhydroquinone activates Akt in myocardium, suppresses apoptosis and ameliorates pressure overload-induced cardiac dysfunctionInhibitory kappa-B kinase-β inhibition prevents adaptive left ventricular hypertrophyTargeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction.The role of the paracrine/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth.Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy.Mitogen-activated protein kinases in heart development and diseasesDeletion of Interleukin-6 Attenuates Pressure Overload-Induced Left Ventricular Hypertrophy and Dysfunction.Acute heart failure with cardiomyocyte atrophy induced in adult mice by ablation of cardiac myosin light chain kinase.Puerarin Attenuates Cardiac Hypertrophy Partly Through Increasing Mir-15b/195 Expression and Suppressing Non-Canonical Transforming Growth Factor Beta (Tgfβ) Signal Pathway.Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling.Autophagy, redox signaling, and ventricular remodeling.Cardiac reanimation: targeting cardiomyocyte death by BNIP3 and NIX/BNIP3L.Having a change of heart: reversing the suicidal proclivities of cardiac myocytes.Divide and conquer: the application of organelle proteomics to heart failure.Desmin modifications associate with amyloid-like oligomers deposition in heart failure.Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy.
P2860
Q24619376-9AAAE2D2-A5ED-4417-B677-1AC999B8D88DQ24654920-C4883F7A-CC43-4028-8A56-1B83A0AE1D48Q28079909-FE1E6C01-4EBA-4AD0-B0C9-CEAF16FB258AQ28296128-60284C6D-76C7-4C7F-9936-381461C50676Q28535743-F4CDD368-6E29-4BD9-ABC4-EF3F860E7E2EQ28594924-90AFE373-6101-4B8B-9566-2B2FCDCA3D1DQ33521236-39F348F9-8792-43B3-A5C1-C59DEEF7055FQ33661644-8ED762B3-BE64-4FF6-9BBA-98871C42E413Q33757346-859095D2-7B3F-4D8D-944B-77DBEE24BDA6Q33764626-2456CCBF-F4F5-4418-A3E6-5FE125FB9A1AQ33854111-E31F9A48-8437-4DC0-8DDC-8AD077A61F5EQ33917163-930971EA-82D8-40B7-BF19-9CD32BD83E84Q34066942-1719DE50-757D-49BF-8F2A-A19C01C6B7D4Q34121511-F935E369-2EE3-4AC6-A383-8C8DF90EA552Q34357873-6CA20743-7069-4FEF-B165-372F43FE0BD7Q34398861-5074D810-2F49-4997-AAC2-0A76803B1665Q34764116-C68AFE9B-6CB3-4C7D-AEAE-5087D750EA2BQ34800455-D119FFDB-773C-4627-883F-D4A593216AC6Q35002059-2416FDE6-D3F0-410B-B6BD-6F8666054045Q35006058-DC1E3A20-4586-4C17-BC77-9DA10BE2F100Q35054529-96389E78-A4A2-4F06-9FE7-935664520C3DQ35076166-D9106F07-F923-41D2-84A7-D1E7B180CFACQ35120578-AFAA87FE-3B84-4B06-9036-8B4263ED2BB9Q35821328-74784221-BD4D-42FE-A0AB-8250723DD8EBQ35936057-342D3E09-877B-4A11-A6B3-898027015214Q36110312-1DB081B3-3D13-4D30-97D7-92CED6F68597Q36415757-2C7A77AD-B10E-4D21-A083-5684AB1C642AQ36610320-C9929824-523C-4D05-A592-5E1A8E1F3105Q36820215-A2FF2857-3206-4DC7-BD24-1B7196ABBE4FQ36944485-DF1CF9B5-7699-4400-B076-5CE7FF603E5CQ36994116-62640D41-EFC0-4AEC-86AD-DC4CDA62597BQ37007966-5CFFB02D-B788-4EBE-87CB-DC3DD680F28AQ37024990-F048114B-B8D9-46B5-A650-4B9254B6BA1CQ37263689-B3212264-902C-4204-A025-DB1DC2A5FDF7Q37425204-E98A58F7-5AC3-48F3-9722-D2D88FA78210Q37566215-2E455A03-4C72-4025-9FB5-B66F5D0624E4Q37600641-4211531F-19ED-4D78-AB18-BA06939CEC06Q37605842-848C4053-272B-4860-9AE0-BBE8A0E962F1Q37644759-194C6FB8-95CA-46C2-B91C-2B5DA8A9A213Q37652498-EC849508-E527-4DBD-B70B-03DD8614528E
P2860
Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets.
@ast
Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets.
@en
type
label
Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets.
@ast
Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets.
@en
prefLabel
Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets.
@ast
Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets.
@en
P2860
P1433
P1476
Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets.
@en
P2093
Abhinav Diwan
Gerald W Dorn
P2860
P356
10.1152/PHYSIOL.00033.2006
P577
2007-02-01T00:00:00Z